NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%

Reuters

2025/08/12

NeurAxis Inc. <a href="https://laohu8.com/S/QTWO">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%

NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558364966"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558364966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558364966?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558364966","market":"nz","top_or_hot":-1,"title":"NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL6GFrXH:1","article_id":"2558364966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558364966","pubTimestamp":1754996419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic ab","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","NRXS":"Neuraxis, Inc."},"translate_title":"Neuraxis Inc.2025年第二季度：收入飙升46%，运营亏损改善22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NRXS":0.9},"content_text":"NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    \n\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}